Philip Tsai
Vermogen: 945 239 $ op 31-05-2026
Vermogen: 945 239 $ op 31-05-2026
Philip Tsai is Chief Technical Officer at Immunome, Inc. since 2024.
Dr. Tsai was Senior Vice President-Technical Development at Seagen, Inc. from 2021 to 2024.
Education includes graduate and doctorate degrees from California Institute of Technology and an undergraduate degree from the University of Illinois At Urbana–Champaign.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMMUNOME, INC. 0,04% | 19-12-2025 | 43.300 ( 0,04% ) | 945 239 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMUNOME, INC. | Hoofd Techniek/Wetenschap/O&O | 27-06-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
| SEAGEN INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2024 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Immunome, Inc.
Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
California Institute of Technology
California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau